About Us

Changzhou Institute of Pharmaceutical Research Co., Ltd. is an innovative national high-tech enterprise specializing in the research, development, production, and sales of medical device products. The company is located at No. 1025, Liahe Road, National High-tech Zone (New North District), Changzhou, Jiangsu Province. Its predecessor was a provincial scientific research institution established in 1984, and it was the earliest scientific research institution in China dedicated to the research of medical sodium hyaluronate gel. It was restructured into an enterprise in 2010.
The company currently has more than 240 employees, including 60 full-time scientific researchers, among whom there are 9 doctors, 40 masters. The team includes 2 Industrial Professors in Jiangsu Province, 1 "Double Creation Talent" in Jiangsu Province, 2 "Double Creation Doctors" in Jiangsu Province, and 7 postdoctoral researchers. There are 4 employees with senior professional titles and 15 with intermediate professional titles. In addition, many discipline leaders, such as academicians of the Chinese Academy of Engineering, and those from Nanjing Normal University and the First Affiliated Hospital of Xi'an Jiaotong University, serve as expert consultants.
The company has established 1 national - level scientific research platform and 4 provincial - level scientific research platforms. The enterprise has successively been rated as a national specialized and sophisticated "Little Giant" enterprise, a Jiangsu Gazelle enterprise, a Jiangsu - level Five - Star Cloud - enabled enterprise, and a private science and technology enterprise in Jiangsu Province. It has been approved to establish scientific research platforms such as a national postdoctoral research station, the Jiangsu Biomedical Materials Engineering Research Center, the Jiangsu Biomedical Materials Engineering Technology Research Center, the Jiangsu Foreign Expert Workstation, and the Jiangsu Enterprise Postgraduate Workstation. In June 2017, the company fully invested in the establishment of Changzhou Yunyu Biomaterials Research Institute, which is responsible for scientific research on new biomedical materials.

The company attaches great importance to scientific and technological research and development, technical cooperation, and intellectual property protection. The enterprise has successively signed industry - university - research cooperation agreements with the Institute of Natural and Medical Sciences (NMI) at the University of Tübingen in Germany, Nanjing Normal University, China Pharmaceutical University, Nanjing University of Science and Technology, Jiangnan University, Xi'an Jiaotong University, etc., to jointly develop biomedical products. The enterprise currently has 60 authorized patents, including 30 authorized invention patents, 12 utility model patents, and 18 design patents.
The company is a member of the Global Harmonization Working Party (GHWP) for medical device regulations. It has successively passed the certifications of ISO9001:2015 Quality Management System, ISO13485:2016 Medical Device Quality Management System, GB/T23001 - 2017 Requirements for the Integration of Informatization and Industrialization Management System, and GB/T23006 - 2022 Grading Requirements for New - type Capabilities of the Integration of Informatization and Industrialization Management System.
The main business directions of the enterprise are medical devices, medical materials, and medical skin care products. The product categories include surgical, ophthalmic, medical cosmetology, and skin care products, forming three major brand series mainly represented by Yishukang, Bicuishi, and Mishui Zhiting. Among them, there are 3 Class III medical device products and 1 Class II medical device product. The related products cover nearly 2,000 medical institutions in most provinces, cities, and autonomous regions in China.
Upholding the corporate vision of "Making humanity healthier and life more beautiful", in the future, the company will continue to deeply cultivate the segmented fields, focus on key core technologies, and strive to become a technology - based enterprise with research and development advantages, marketable products, profitable operations, and development potential. It will gradually build itself into a high - quality and innovative biomedical materials research center with international influence.